Cincinnati Children's Vector Production Facility

Cincinnati, OH
National Center
AAV Lentiviral
1 confirmed programs · 1 sponsors · Last scored 2026-04-02
75.2
Signal Score
✓ FDA Inspections (1) ✓ Clinical Trials (1) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Cincinnati Children's Vector Production Facility

Signal Score
75.2/100 (as of 2026-04-02)
Quality Compliance
100.0/100
Headquarters
Cincinnati, OH
Modalities
AAV, Lentiviral
Active Programs
1 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-02-05)
Operations 60.0
1 active programs across 1 sponsors
Modalities: AAV, Lentiviral
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
1 active programs across 1 sponsors · Modalities: AAV, Lentiviral · 1 programs in advanced phases (Phase 2/3)
Programs 1
Sponsors1
ModalitiesAAV, Lentiviral
1 active programs across 1 sponsors
Modalities: AAV, Lentiviral
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT00537394 Optimizing Treatment for Treatment-Experienced, HIV-Infected People PHASE3 Completed
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability 68.0
Parent company: Cincinnati Children's Hospital
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Cincinnati Children's Hospital
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Cincinnati, OH
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Cincinnati, OH
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Cincinnati, OH
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100

FDA Inspection History

2025-02
NAI VAI OAI
Date Site Type Observations Classification
2025-02-05 Cincinnati, Ohio Human Cellular, Tissue, and Gene Therapies No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Apr 05, 2026

Clinical Activity 1 studies

NCT00537394 Optimizing Treatment for Treatment-Experienced, HIV-Infected People PHASE3 Completed
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, CN
Signal Score: 85.6
AAV, Lentiviral, Plasmid
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.2
AAV, Lentiviral, Plasmid DNA, Adenoviral
BioReliance (Merck)
Glasgow, UK · Rockville, MD
Signal Score: 81.5
AAV, Lentiviral, Biologics